A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Lecanemab was approved by regulators in the US, the UK, and other countries. Still, it failed last July to get approval from the EMA’s Committee for Medicinal Products for Human Use (CHMP).

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...